Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BDKRB1 | P46663 | 4/20 | 0.51 |
| ▸ | PTGER4 | P35408 | 5/20 | 0.45 |
| ▸ | PTGER2 | P43116 | 2/20 | 0.45 |
| ▸ | CXCR4 | P61073 | 1/20 | 0.43 |
| ▸ | MAPK14 | Q16539 | 3/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CNR1 | P21554 | 1/20 | 0.37 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.36 |
| ▸ | CARM1 | Q86X55 | 1/20 | 0.36 |
| ▸ | PRMT6 | Q96LA8 | 1/20 | 0.36 |
| ▸ | METAP2 | P50579 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12262021 | 0.90 | BDKRB1 (0.56) | BDKRB1CYP3A4L3MBTL1 | |
| SCHEMBL765831 | 0.89 | BDKRB1 (0.51) | BDKRB1PTGER4PTGER2CXCR4MAPK14 | |
| SCHEMBL765204 | 0.89 | BDKRB1 (0.51) | BDKRB1PTGER4PTGER2CXCR4MAPK14 | |
| SCHEMBL10121385 | 0.89 | BDKRB1 (0.53) | BDKRB1PTGER4PTGER2CXCR4MAPK14 | |
| SCHEMBL12239087 | 0.89 | BDKRB1 (0.53) | BDKRB1MAPK14CYP3A4CNR1L3MBTL1 | |
| SCHEMBL12238924 | 0.89 | BDKRB1 (0.51) | BDKRB1PTGER4PTGER2MAPK14CYP3A4 | |
| SCHEMBL765553 | 0.89 | BDKRB1 (0.58) | BDKRB1MAPK14CYP3A4CNR1L3MBTL1 | |
| SCHEMBL10121362 | 0.88 | BDKRB1 (0.58) | BDKRB1PTGER4PTGER2CXCR4MAPK14 | |
| SCHEMBL764449 | 0.87 | BDKRB1 (0.49) | BDKRB1PTGER4PTGER2CXCR4MAPK14 | |
| SCHEMBL13904120 | 0.86 | BDKRB1 (0.50) | BDKRB1PTGER4PTGER2MAPK14CNR1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8916589-B2 | Bradykinin B1-antagonists | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2014-12-23 | — | — | US | disclosed |
| EP-2188254-B1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INT (DE) | 2012-03-21 | — | — | EP | disclosed |
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2011-10-27 | — | — | US | disclosed |
| WO-2009027450-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BOEHRINGER INGELHEIM INTERNATIONAL GMBH (DE) | 2009-03-05 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110263626-A1 | NOVEL BRADYKININ B1-ANTAGONISTS | BDKRB1, BDKRB2, EDNRB | BDKRB1 1/4885PTGER4 185/4885PTGER2 233/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.